NDA 020215 · Omnivium Pharms
Monoket
Isosorbide Mononitrate · Oral · Nitrate Vasodilator
Last checked: Nov 20, 2026Latest source record: Feb 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jun 30, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
88
18 Phase 3, 4 recruiting
FAERS reports
20,958
17,559 serious, 2,621 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 5, 2025.
INDICATIONS AND USAGE: Isosorbide Mononitrate Tablets are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 30, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- MONOKET · ISOSORBIDE MONONITRATE 20MG · TABLET, ORAL · Prescription · TE AB
- MONOKET · ISOSORBIDE MONONITRATE 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Isosorbide Mononitrate" as an intervention, any sponsor and status, largest first.
- Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)Pivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07252544 · 3,156 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 31, 2027
Drug: Isosorbide Mononitrate; Butylphthalide and 2 more · For: Stroke, Lacunar; Stroke, Acute Ischemic; Cerebral Small Vessel Diseases
- Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP PreventionPivotal-lookingStatus unknown
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT04425993 · 2,700 participants · Start Jul 1, 2020 · Primary completion May 30, 2022
Drug: Isosorbide Dinitrate 5 MG; Indomethacin 100 MG and 2 more · For: Post-ERCP Acute Pancreatitis
Sites: Xiamen, China; Lanzhou, China; Xi'an, China · 4 sites in all
- Intensive Arterial Pressure Control in Acute Coronary SyndromePivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT02135315 · 1,500 participants · Start Mar 2014 · Primary completion Dec 31, 2020
Drug: Isosorbide Dinitrate · For: Acute Coronary Syndrome
Sites: Monastir, Tunisia
- Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary InterventionPivotal-lookingCompleted
Pr. Semir NouiraAcademic, hospital or other
NCT04538534 · 1,500 participants · Start Nov 1, 2020 · Primary completion Feb 1, 2022
Drug: Nicardipine · For: Spasm Artery
Sites: Monastir, Tunisia
- Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term PregnanciesPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00930618 · 1,409 participants · Start Jun 2009 · Primary completion Dec 2013
Drug: IMN; Placebo · For: Prolonged Pregnancy; Nulliparity
Sites: Paris, France
- DANHEART (H-HeFT and Met-HeFT)Pivotal-lookingCompleted
Henrik WiggersAcademic, hospital or other
NCT03514108 · 1,100 participants · Start Mar 1, 2018 · Primary completion Dec 31, 2025
Drug: Hydralazine Isosorbide Dinitrate; Placebo Oral Tablet and 2 more · For: Heart Failure; Diabetes
Sites: Holbæk, Denmark; Aabenraa, Denmark; Aalborg, Denmark · 26 sites in all
- African-American Heart Failure TrialPivotal-lookingCompleted
NitromedIndustry
NCT00047775 · 1,100 participants · Start May 2001
Drug: BiDil · For: Congestive Heart Failure
Sites: Birmingham, Alabama; Little Rock, Arkansas; Washington D.C., District of Columbia · 7 sites in all
- Baroreflex Activation Therapy for Heart FailurePivotal-lookingCompleted
CVRx, Inc.Industry
NCT02627196 · 1,090 participants · Start Apr 19, 2016 · Primary completion Oct 2023
Drug: Medical Management · For: Heart Failure
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 92 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,592
- dizziness1,487
- diarrhoea1,331
- fatigue1,328
- nausea1,301
- chest pain1,239
- headache1,095
- myocardial infarction1,074
- vomiting998
- hypotension960
- off label use951
- malaise947
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 456 |
| 2005 | 540 |
| 2006 | 517 |
| 2007 | 396 |
| 2008 | 616 |
| 2009 | 518 |
| 2010 | 455 |
| 2011 | 661 |
| 2012 | 820 |
| 2013 | 533 |
| 2014 | 858 |
| 2015 | 1,022 |
| 2016 | 1,162 |
| 2017 | 1,198 |
| 2018 | 1,477 |
| 2019 | 1,416 |
| 2020 | 1,179 |
| 2021 | 973 |
| 2022 | 1,266 |
| 2023 | 1,527 |
| 2024 | 1,154 |
| 2025 | 1,256 |
| 2026 | 953 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Wardlaw JM, Woodhouse LJ, Mhlanga II, et al. · JAMA Neurol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Isosorbide mononitrate for cervical ripening during labour induction: A systematic review and meta-analysis of 23 randomized controlled trials.
Abu-Zaid A, Alshahrani MS, Al-Matary A, et al. · Eur J Obstet Gynecol Reprod Biol 2022 · Meta-Analysis, Systematic Review
- Isosorbide Mononitrate Versus Dinoprostone for Cervical Ripening During Labor Induction: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Abu-Zaid A, Khadawardi K, Al-Matary A, et al. · Reprod Sci 2023 · Meta-Analysis, Systematic Review
- Misoprostol plus isosorbide mononitrate versus misoprostol alone for cervical ripening during labor induction: A systematic review and meta-analysis of randomized controlled trials.
Abuzaid M, Baradwan S, Alkhamis WH, et al. · J Gynecol Obstet Hum Reprod 2022 · Meta-Analysis, Systematic Review
- Efficacy and safety of isosorbide mononitrate plus misoprostol compared to misoprostol alone in the management of the first and second trimester abortion: a systematic review and meta-analysis.
Makvandi S, Karimi L, Safyari M, et al. · BMC Pregnancy Childbirth 2024 · Systematic Review, Meta-Analysis
- Long-acting cilostazol versus isosorbide mononitrate for patients with vasospastic angina: a randomized controlled trial.
Kang MG, Ahn JH, Hwang JY, et al. · Coron Artery Dis 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Omnivium Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.